DK0617616T3 - Potensering af NMDA-antagonister - Google Patents

Potensering af NMDA-antagonister

Info

Publication number
DK0617616T3
DK0617616T3 DK92925469T DK92925469T DK0617616T3 DK 0617616 T3 DK0617616 T3 DK 0617616T3 DK 92925469 T DK92925469 T DK 92925469T DK 92925469 T DK92925469 T DK 92925469T DK 0617616 T3 DK0617616 T3 DK 0617616T3
Authority
DK
Denmark
Prior art keywords
potentiation
nmda antagonists
antagonists
nmda
poteniating
Prior art date
Application number
DK92925469T
Other languages
Danish (da)
English (en)
Inventor
Bruce M Baron
Ian A Mcdonald
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of DK0617616T3 publication Critical patent/DK0617616T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK92925469T 1991-12-20 1992-12-01 Potensering af NMDA-antagonister DK0617616T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/811,204 US5318985A (en) 1991-12-20 1991-12-20 Potentiation of NMDA antagonists
PCT/US1992/010354 WO1993012780A1 (en) 1991-12-20 1992-12-01 Potentiation of nmda antagonists

Publications (1)

Publication Number Publication Date
DK0617616T3 true DK0617616T3 (da) 2000-04-17

Family

ID=25205874

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92925469T DK0617616T3 (da) 1991-12-20 1992-12-01 Potensering af NMDA-antagonister

Country Status (10)

Country Link
US (2) US5318985A (de)
EP (1) EP0617616B1 (de)
JP (1) JPH07504890A (de)
AT (1) ATE185969T1 (de)
AU (1) AU667333B2 (de)
CA (1) CA2124799A1 (de)
DE (1) DE69230224T2 (de)
DK (1) DK0617616T3 (de)
NZ (1) NZ246114A (de)
WO (1) WO1993012780A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2608507A (en) * 1949-08-20 1952-08-26 Sharp & Dohme Inc Dialkyl sulfamyl benzoic acids
US2608508A (en) * 1949-08-20 1952-08-26 Sharp & Dohme Inc N-amylsulfamyl benzoic acids
JPS5756425A (en) * 1980-09-20 1982-04-05 Santen Pharmaceut Co Ltd Hypotensor
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5095009A (en) * 1990-04-11 1992-03-10 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
DE4021545A1 (de) * 1990-07-06 1992-01-16 Engineering Der Voest Alpine I Verfahren und vorrichtung zum herstellen von kunststoffaeden oder -fasern aus polymeren, insbesondere polyamid, polyester oder polypropylen
KR0178469B1 (ko) * 1990-07-16 1999-03-20 메이나드 알. 존슨 흥분성 아미노산 길항제
JP3465794B2 (ja) * 1991-02-27 2003-11-10 メレルファーマスーティカルズ インコーポレイテッド Nmda拮抗剤
DK0501378T3 (da) * 1991-02-28 1995-03-20 Merrell Dow Pharma NMDA-antagonister
CA2115442C (en) * 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist

Also Published As

Publication number Publication date
CA2124799A1 (en) 1993-07-08
AU3150993A (en) 1993-07-28
JPH07504890A (ja) 1995-06-01
DE69230224T2 (de) 2000-04-13
EP0617616B1 (de) 1999-10-27
EP0617616A1 (de) 1994-10-05
NZ246114A (en) 1995-10-26
US5318985A (en) 1994-06-07
US5489579A (en) 1996-02-06
WO1993012780A1 (en) 1993-07-08
DE69230224D1 (de) 1999-12-02
ATE185969T1 (de) 1999-11-15
AU667333B2 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
DK93892D0 (da) Fremgangsmaade til fremstilling af et depotpraeparat
YU25497A (sh) Postupak za dobijanje sildenafila
DK0617616T3 (da) Potensering af NMDA-antagonister
ES2194003T3 (es) Huperzina a racemica.
FI914187L (fi) Menetelmä valmistaa kaavan /I/ mukaista 1-metyylikarbapeneemijohdosta
NO930035L (no) Eksitatoriske aminosyreantagonister
DK0535900T3 (da) Ettrinsfremgangsmåde til fremstilling af dirithromycin
DK23790A (da) Doseringsform til administrering af en calciumantagonist
CZ282732B6 (cs) Substituované 1,2,3,4-tetrahydrocyklopent/b/indoly, 1,2,3,3a,4,8a-hexahydrocyklopent/b/indoly a příbuzné sloučeniny, meziprodukty a způsob jejich přípravy a jejich použití jako léčiv
DK0526478T3 (da) 3-Indolyl-thioacetat-derivater
FI920880A7 (fi) NMDA-antagonisteja
NO924361L (no) Formazan parasittiske midler
ATE137225T1 (de) Dihydrochinolin nmda antagonisten
FI973235A0 (fi) Menetelmä IL-6:n vaikutusten inhiboimiseksi
GR1001566B (el) Μέ?οδος παρασκευής νέων παραγώγων βενζοφουρανυλιμιδαζόλης.
DK0457324T3 (da) Heterocycliske NMDA antagonister
FI940338L (fi) Menetelmä 13alfa-sinnamoyylibakkatiini III:n tai -10-desasetyylibakkatiini III:n valmistamiseksi
SE9102571D0 (sv) A novel method of generating clones for the expression of unfused proteins
FI922096A7 (fi) Tetrahydro-5-substituoitu-3-metyleeni-2-furaanimetanolien stereo- ja enantioselektiivinen synteesi
FI942248A7 (fi) N-trityyliasparagiinihapon johdannaiset fosfonaatti-NMDA-antagonistien valmistamiseksi
MX9205607A (es) Procedimiento para la preparacion de: griseofulvina
GR1001368B (el) Φαρμακευτικοί φορείς.
NO930438D0 (no) Demonterbar laas
ITRM910239V0 (it) Protesi fonetica per laringectomizzati